Syrris has been appointed distributor of the Lara controlled lab reactor (CLR) and the Coflux reaction monitoring and calorimetry system in North America
The Lara CLR is a flexible and modular chemical reactor that is both affordable and highly automated.
It can accommodate variable vessel size, ranging from 100ml to five litres, and it incorporates easy-to-use software which allows extensive reaction design and full data logging.
The Coflux (constant flux) system uses the Lara CLR software to gather real-time reaction data such as power and enthalpy change.
With minimal calibration, accurate temperature measurements are afforded through a uniquely designed thermal jacket comprising of numerous coolant tubes surrounding the reaction vessel.
Making the announcement, Richard Gray, commercial director, said "We have experienced great success with the Lara CLR and Coflux products and our expanding client base reaches across the USA, including major pharma companies such as GSK and Pfizer.
"This new appointment by Radleys ensures that customers in North America will receive the very best sales and technical support".
Mark Radley, managing director of Radleys, commented: "We're confident Lara will offer significant benefits to customers in North America.
"Syrris worked closely with us on the design and development of both Lara and Coflux, and so has great knowledge of these products and is in the ideal position to service the US market".
Syrris will be exhibiting Lara and Coflux at the forthcoming Cambridge Healthcare Institute Process R and D Summit in Philadelphia 24-26 October.
Established in 2001, Syrris is one of the fastest growing science SMEs in the UK employing 20 scientists at its facility in Royston (near Cambridge, UK).
Founders Mark Gilligan and Richard Gray come from a background of developing automation products for chemists at companies such as The Technology Partnership (TTP) and Mettler Toledo Automated Chemistry.
Syrris is creating a family of flow reactor products for discovery and development chemists.
The objective is to reduce the taken time to develop, synthesise, screen and review a chemical entity, from weeks to seconds, thus vastly speeding up the drug discovery process.
Syrris also develops productivity tools in partnership with other companies.
In recognition of its technological achievements, Syrris was awarded a UK DTI Smart Exceptional Grant of £400k in 2003 - one of only 11 to have been awarded since 1998.
